185 related articles for article (PubMed ID: 21135181)
21. Evidence for low risk of Clostridium difficile infection associated with tigecycline.
Wilcox MH
Clin Microbiol Infect; 2007 Oct; 13(10):949-52. PubMed ID: 17697004
[TBL] [Abstract][Full Text] [Related]
22. Toxins, butyric acid, and other short-chain fatty acids are coordinately expressed and down-regulated by cysteine in Clostridium difficile.
Karlsson S; Lindberg A; Norin E; Burman LG; Akerlund T
Infect Immun; 2000 Oct; 68(10):5881-8. PubMed ID: 10992498
[TBL] [Abstract][Full Text] [Related]
23. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.
Barbut F; Decré D; Burghoffer B; Lesage D; Delisle F; Lalande V; Delmée M; Avesani V; Sano N; Coudert C; Petit JC
Antimicrob Agents Chemother; 1999 Nov; 43(11):2607-11. PubMed ID: 10543736
[TBL] [Abstract][Full Text] [Related]
24. Tigecycline for the treatment of severe Clostridium difficile infection.
Larson KC; Belliveau PP; Spooner LM
Ann Pharmacother; 2011 Jul; 45(7-8):1005-10. PubMed ID: 21730279
[TBL] [Abstract][Full Text] [Related]
25. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile.
Drudy D; Harnedy N; Fanning S; Hannan M; Kyne L
Infect Control Hosp Epidemiol; 2007 Aug; 28(8):932-40. PubMed ID: 17620240
[TBL] [Abstract][Full Text] [Related]
26. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 Mar; 56(3):1613-5. PubMed ID: 22183166
[TBL] [Abstract][Full Text] [Related]
27. IMPACT OF TIGECYCLINE VERSUS OTHER ANTIBIOTICS ON THE FECAL METABOLOME AND ON COLONIZATION RESISTANCE TO
Jump RL; Kraft D; Hurless K; Polinkovsky A; Donskey CJ
Pathog Immun; 2017 Jan; 2(1):1-20. PubMed ID: 28217763
[TBL] [Abstract][Full Text] [Related]
28. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study.
Gergely Szabo B; Kadar B; Szidonia Lenart K; Dezsenyi B; Kunovszki P; Fried K; Kamotsay K; Nikolova R; Prinz G
Clin Microbiol Infect; 2016 Dec; 22(12):990-995. PubMed ID: 27599690
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of LFF571 in a hamster model of Clostridium difficile infection.
Trzasko A; Leeds JA; Praestgaard J; Lamarche MJ; McKenney D
Antimicrob Agents Chemother; 2012 Aug; 56(8):4459-62. PubMed ID: 22644020
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
Kumar M; Mathur T; Barman TK; Ramkumar G; Bhati A; Shukla G; Kalia V; Pandya M; Raj VS; Upadhyay DJ; Vaishnavi C; Chakrabarti A; Das B; Bhatnagar PK
Antimicrob Agents Chemother; 2012 Nov; 56(11):5986-9. PubMed ID: 22869573
[TBL] [Abstract][Full Text] [Related]
31. Clostridium difficile--a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis.
Borriello SP; Ketley JM; Mitchell TJ; Barclay FE; Welch AR; Price AB; Stephen J
J Med Microbiol; 1987 Aug; 24(1):53-64. PubMed ID: 3612744
[TBL] [Abstract][Full Text] [Related]
32. Failure of tigecycline to treat severe Clostridium difficile infection.
Kopterides P; Papageorgiou C; Antoniadou A; Papadomichelakis E; Tsangaris I; Dimopoulou I; Armaganidis A
Anaesth Intensive Care; 2010 Jul; 38(4):755-8. PubMed ID: 20715744
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
Nagy E; Dowzicky MJ
Scand J Infect Dis; 2010; 42(1):33-8. PubMed ID: 19883155
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.
Swanson RN; Hardy DJ; Shipkowitz NL; Hanson CW; Ramer NC; Fernandes PB; Clement JJ
Antimicrob Agents Chemother; 1991 Jun; 35(6):1108-11. PubMed ID: 1929250
[TBL] [Abstract][Full Text] [Related]
35. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 May; 56(5):2493-503. PubMed ID: 22290948
[TBL] [Abstract][Full Text] [Related]
36. Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection.
Chilton CH; Crowther GS; Śpiewak K; Brindell M; Singh G; Wilcox MH; Monaghan TM
J Antimicrob Chemother; 2016 Apr; 71(4):975-85. PubMed ID: 26759363
[TBL] [Abstract][Full Text] [Related]
37. The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study.
Manea E; Sojo-Dorado J; Jipa RE; Benea SN; Rodríguez-Baño J; Hristea A
Clin Microbiol Infect; 2018 Feb; 24(2):180-184. PubMed ID: 28642147
[TBL] [Abstract][Full Text] [Related]
38. Activity of tigecycline against recent European clinical isolates of Clostridium difficile.
Hawser SP
Int J Antimicrob Agents; 2010 Jan; 35(1):97-8. PubMed ID: 19892528
[No Abstract] [Full Text] [Related]
39. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile.
Britton RA; Young VB
Gastroenterology; 2014 May; 146(6):1547-53. PubMed ID: 24503131
[TBL] [Abstract][Full Text] [Related]
40. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
Hecht DW; Galang MA; Sambol SP; Osmolski JR; Johnson S; Gerding DN
Antimicrob Agents Chemother; 2007 Aug; 51(8):2716-9. PubMed ID: 17517836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
